Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies

Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1141-3. doi: 10.1007/s10096-008-0543-1. Epub 2008 Jun 18.

Abstract

Voriconazole has been shown to be safe and effective for fungal infection. However, its population pharmacokinetics for patients with hematological malignancies remains unknown. We performed a population pharmacokinetics study of nine hematological patients with 36 points samples. We approximated the drug concentration curve using a linear one-compartment model. The distribution of volume (Vd), elimination rate constant, and clearance (CL) were 68.7 L, 0.163 h(-1), and 11.2 L/h, respectively. By coincidence, our study has verified that the current administration is enough to treat fungus infections by using Monte Carlo simulation. Our data demonstrated that the current administration method is appropriate and effective. Our results may prove to be useful as a basic reference for the clinical usage of voriconazole.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / pharmacology
  • Asian Continental Ancestry Group
  • Female
  • Hematologic Neoplasms*
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Monte Carlo Method
  • Mycoses / drug therapy
  • Pyrimidines / pharmacokinetics*
  • Pyrimidines / pharmacology
  • Tissue Distribution
  • Triazoles / pharmacokinetics*
  • Triazoles / pharmacology
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole